237 related articles for article (PubMed ID: 12827483)
1. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall.
Martin AR; Pearson JD; Cai B; Elmer M; Horgan K; Lindley C
Support Care Cancer; 2003 Aug; 11(8):522-7. PubMed ID: 12827483
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.
Hilarius DL; Kloeg PH; van der Wall E; van den Heuvel JJ; Gundy CM; Aaronson NK
Support Care Cancer; 2012 Jan; 20(1):107-17. PubMed ID: 21258948
[TBL] [Abstract][Full Text] [Related]
3. Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life.
Abunahlah N; Sancar M; Dane F; Özyavuz MK
Int J Clin Pharm; 2016 Dec; 38(6):1464-1476. PubMed ID: 27796777
[TBL] [Abstract][Full Text] [Related]
4. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy.
Decker GM; DeMeyer ES; Kisko DL
J Support Oncol; 2006 Jan; 4(1):35-41, 52. PubMed ID: 16444851
[TBL] [Abstract][Full Text] [Related]
5. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
6. Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.
Martin AR; Carides AD; Pearson JD; Horgan K; Elmer M; Schmidt C; Cai B; Chawla SP; Grunberg SM
Eur J Cancer; 2003 Jul; 39(10):1395-401. PubMed ID: 12826042
[TBL] [Abstract][Full Text] [Related]
7. The impact of chemotherapy-induced nausea and vomiting on health-related quality of life.
Ballatori E; Roila F; Ruggeri B; Betti M; Sarti S; Soru G; Cruciani G; Di Maio M; Andrea B; Deuson RR
Support Care Cancer; 2007 Feb; 15(2):179-85. PubMed ID: 16941136
[TBL] [Abstract][Full Text] [Related]
8. Quality of life consequences of chemotherapy-induced emesis.
Lindley CM; Hirsch JD; O'Neill CV; Transau MC; Gilbert CS; Osterhaus JT
Qual Life Res; 1992 Oct; 1(5):331-40. PubMed ID: 1299465
[TBL] [Abstract][Full Text] [Related]
9. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
Chasen M; Urban L; Schnadig I; Rapoport B; Powers D; Arora S; Navari R; Schwartzberg L; Gridelli C
Support Care Cancer; 2017 Jan; 25(1):85-92. PubMed ID: 27557833
[TBL] [Abstract][Full Text] [Related]
10. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population.
Haiderali A; Menditto L; Good M; Teitelbaum A; Wegner J
Support Care Cancer; 2011 Jun; 19(6):843-51. PubMed ID: 20532923
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the 3-day recall period for the Functional Life Index-Emesis (FLIE).
Wan BA; Drost L; Ganesh V; Zhang L; Yee C; Tsao M; Barnes E; Pasetka M; DeAngelis C; Chow E
Ann Palliat Med; 2018 Oct; 7(4):393-403. PubMed ID: 30180722
[TBL] [Abstract][Full Text] [Related]
12. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres.
O'Brien BJ; Rusthoven J; Rocchi A; Latreille J; Fine S; Vandenberg T; Laberge F
CMAJ; 1993 Aug; 149(3):296-302. PubMed ID: 8339175
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced nausea and vomiting in routine practice: a European perspective.
Glaus A; Knipping C; Morant R; Böhme C; Lebert B; Beldermann F; Glawogger B; Ortega PF; Hüsler A; Deuson R
Support Care Cancer; 2004 Oct; 12(10):708-15. PubMed ID: 15278682
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings.
Cohen L; de Moor CA; Eisenberg P; Ming EE; Hu H
Support Care Cancer; 2007 May; 15(5):497-503. PubMed ID: 17103197
[TBL] [Abstract][Full Text] [Related]
15. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
[TBL] [Abstract][Full Text] [Related]
16. Symptom clusters of gastrointestinal cancer patients undergoing radiotherapy using the Functional Living Index-Emesis (FLIE) quality-of-life tool.
Poon M; Dennis K; DeAngelis C; Chung H; Stinson J; Zhang L; Bedard G; Wong E; Popovic M; Lao N; Pulenzas N; Wong S; Cheon P; Chow E
Support Care Cancer; 2015 Sep; 23(9):2589-98. PubMed ID: 25620759
[TBL] [Abstract][Full Text] [Related]
17. [Development of a Japanese version of the FLIE].
Satou A; Yamazaki T; Nukariya N; Nakamachi M; Shimada K; Matsukawa M; Kurihara M
Gan To Kagaku Ryoho; 2002 Feb; 29(2):281-91. PubMed ID: 11865635
[TBL] [Abstract][Full Text] [Related]
18. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
19. Herbal medicine for the prevention of chemotherapy-induced nausea and vomiting in patients with advanced colorectal cancer: A prospective randomized controlled trial.
Wu Z; Fu X; Jing H; Huang W; Li X; Xiao C; Li Z; You F
J Ethnopharmacol; 2024 May; 325():117853. PubMed ID: 38341113
[TBL] [Abstract][Full Text] [Related]
20. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' quality of life: An Arabic version of the Functional Living Index-Emesis.
Alhammad AM; Alkhudair N; Alzaidi R; Almosabhi LS; Aljawadi MH
J Oncol Pharm Pract; 2022 Apr; 28(3):535-541. PubMed ID: 33645326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
